Items Tagged ‘Chronic Myeloid Leukemia’

April 7th, 2015

Tasigna® Remains Superior to Gleevec® for Treatment of Newly Diagnosed Patients With Chronic Myeloid Leukemia

By

Tasigna® (nilotinib) remains superior to Gleevec® (imatinib) for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (PH+CML), according to the results of the six-year update from the ENESTnd trial which were presented at the 56th annual meeting of the American Society of Hematology (ASH) in San Francisco.  These data are consistent with that […]

View full entry

Tags: Chronic Myeloid Leukemia, CML, ENESTnd trial, Gleevec, imatinib, Leukemia, News, nilotinib, Philadelphia chromosome positive, Tasigna


February 21st, 2014

SYNRIBO® Approved for use in Chronic Myeloid Leukemia

By

The U.S. Food and Drug Administration (FDA) has granted full approval of SYNRIBO® (omacetaxine mepesuccinate) for injection. SYNRIBO is indicated for adult patients with chronic phase (CP +0.28%, news) or accelerated phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).  SYNRIBO® is indicated for the treatment […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


January 4th, 2013

Iclusig Approved for CML and ALL

By

The U.S. Food and Drug Administration (FDA) has approved Iclusig™ (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases. Chronic myeloid leukemia (CML) is the abnormal growth of relatively mature myeloid (white blood) cells. Acute lymphoblastic leukemia (ALL) is a […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, News


December 21st, 2012

Tasigna Superior to Gleevec for Philadelphia Chromosome-Positive CML

By

Tasigna® (nilotinib) is superior to Gleevec® (imatinib) for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML), according to the results of two studies presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia. Each year in the United States, approximately 5,000 people are diagnosed with chronic myeloid […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


November 8th, 2012

Synribo Approved for CML

By

The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults. Each year in the United States, approximately 5,000 people are diagnosed with CML. Most cases of CML are characterized by a chromosomal abnormality—the Philadelphia chromosome—in […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


September 26th, 2012

Bosulif Approved for CML

By

The U.S. Food and Drug Administration (FDA) has approved Bosulif® (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults. The drug is intended for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML who are resistant to or who cannot tolerate other therapies, including […]

View full entry

Tags: Chronic Myeloid Leukemia, News


August 13th, 2012

Ponatinib Produces High Response Rates in CML

By

Ponatinib, an investigational targeted agent, appears to be significantly effective in treatment-refractory chronic myeloid leukemia (CML) and produces early and lasting responses, according to the preliminary results of a study presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. Each year in the United States, approximately 5,000 […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


October 17th, 2011

New Warning Added to Sprycel Label

By

The US Food and Drug Administration (FDA) announced that Sprycel® (dasatinib) may increase the risk of a rare but serious condition known as pulmonary arterial hypertension. Sprycel is a targeted therapy used to treat selected adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL). Pulmonary arterial hypertension (PAH) is a […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Leukemia, News


October 14th, 2011

Bosutinib Shows Promise for Second-Line CML Treatment

By

Treatment with the investigational drug bosutinib produced promising rates of response among patients with chronic-phase chronic myeloid leukemia (CML) that had previously been treated with Gleevec® (imatinib). The results of this Phase I/II trial were published in Blood. Each year in the United States, approximately 5,000 people are diagnosed with CML. Most cases of CML […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


September 7th, 2011

Tasigna Continues to Show Benefit for Newly Diagnosed CML

By

According to updated results from a Phase III clinical trial, Tasigna® (nilotinib) continues to be more effective than Gleevec® (imatinib) for the initial treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. These results were published in Lancet Oncology. Each year in the United States, approximately 5,000 […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


June 17th, 2011

Bosutinib Evaluated for Initial Treatment of Patients with CML

By

Researchers involved in an international study have reported that a new tyrosine kinase inhibitor, bosutinib, appears to be superior to Gleevec® (imatinib) for the initial therapy of patients with chronic myeloid leukemia (CML). The early results of this randomized trial were presented at the 2011 meeting of the American Society of Clinical Oncology. Each year […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


May 23rd, 2011

Many Patients with “Chemo Brain” Recover within Five Years

By

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist for more than five years after treatment. These findings were recently reported in the Journal of Clinical Oncology. Chemo brain refers […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Adult Acute Lymphoblastic Leukemia, Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Allogeneic Stem Cell Transplant, Childhood Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Early Stage Hodgkin's Lymphoma


March 31st, 2011

CML Patients Treated with Gleevec Have Normal Life Expectancy

By

People with chronic myeloid leukemia (CML) that is in complete remission after two years of treatment with Gleevec® (imatinib) have survival rates that are similar to those of the general population. These results were published in the Journal of the National Cancer Institute. Each year in the United States, approximately 5,000 people are diagnosed with […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia


January 28th, 2010

Tasigna May Be More Effective than Gleevec for Initial Treatment of CML

By

In the initial treatment of chronic myeloid leukemia (CML), Tasigna® (nilotinib) appears to produce higher response rates than Gleevec® (imatinib) 400 mg/day. These results were presented at the 2009 meeting of the American Society of Hematology (ASH). CML is a cancer that originates in the immune cells. It affects approximately 5,000 people annually in the […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


March 20th, 2009

Cancer's Glamour Girl

By

Down-to-earth and down-to-business when it comes to cancer advocacy, Erin Zammett Ruddy discusses her very public journey with chronic myeloid leukemia and why she continues to share her story. by Diana Price Erin Zammett Ruddy always wanted to be famous—at least a little bit. In My (So-Called) Normal Life, the memoir she wrote after she […]

View full entry

Tags: Chronic Myeloid Leukemia